Entrada Developing Enzyme Replacement Therapy ENTR-501 to Treat MNGIE Disease

Print Friendly, PDF & Email

Entrada Therapeutics is developing an enzyme replacement therapy, called ENTR-501, as a potential new treatment strategy for people with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). MNGIE is a rare inherited disease caused by mutations in the nuclear TYMP gene, which encodes the thymidine phosphorylase (TP) enzyme. Low or no TP causes […]